Clinical trialNCT02604368UnknownPhase 3Interventional

A Sickle CEll Disease ComplicatioN Trial

SponsorMicelle BioPharma IncEnrollment210Sickle Cell Disease

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The objective of this study is to assess the efficacy of SC411 in reducing the number of sickle cell crisis (SCC) events in sickle cell disease (SCD) subjects receiving SC411 compared to those subjects receiving placebo.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Beng Fuh, MD
East Carolina University
Study Chair
clinicaltrials.gov ↗
Carton Dampier, MD
Emory University
Study Chair
clinicaltrials.gov ↗
Matt Heeney, MD
Harvard University
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PlaceboSC411

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Mar 2019
Primary completion: 31 Dec 2020
Completion: 31 Dec 2020
Last update posted: 1 Feb 2019
Registered enrollment: 210
Registry id: NCT02604368

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.